Human recombinant monoamine oxidase B as reliable and efficient enzyme source for inhibitor screening

Interest in inhibitors of monoamine oxidase type B (MAO B) has grown in recent years, due to their therapeutic potential in aging-related neurodegenerative diseases, such as Parkinson’s disease and Alzheimer’s disease. This study is devoted to the use of human recombinant MAO B obtained from a Baculovirus expression system (Supersomes™ MAO B, BD Gentest, MA, USA) as reliable and efficient enzyme source for MAO B inhibitor screening. Comparison of inhibition potencies (pIC50 values) determined with human cloned and human platelet MAO B for the two series of MAO B inhibitors, coumarin and 5H-indeno[1,2-c]pyridazin-5-one derivatives, showed that the difference between pIC50 values obtained with the two enzyme sources was not significant (P > 0.05, Student’s t-test). Hence, recombinant enzyme is validated as convenient enzyme source for MAO B inhibitor screening.

The reliability of human recombinant monoamine oxidase B (Supersomes™ MAO B, BD Gentest, MA, USA) as an enzyme source for MAO B inhibitor screening was validated by comparison of inhibition potencies (pIC50 values) determined with human-cloned and human platelet MAO B for the two series of MAO B inhibitors, coumarin (C) and 5H-indeno[1,2-c]pyridazin-5-one (IP) derivatives.Figure optionsDownload as PowerPoint slide